{
    "clinical_study": {
        "@rank": "163181", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Eletriptan 20 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Eletriptan 40 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Eletriptan 80 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in\n      relieving symptoms of acute migraine and to further explore the dose response relationship\n      of eletriptan."
        }, 
        "brief_title": "Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine", 
        "completion_date": {
            "#text": "December 1997", 
            "@type": "Actual"
        }, 
        "condition": "Migraine With or Without Aura", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of at least one typical attack of migraine with or without aura every 6\n             weeks, as defined by the International Headache Society (IHS) criteria.\n\n          -  Capable of taking study medication as outpatients and recording its effects.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding women\n\n          -  Migraine subjects who also suffered from concomitant frequent (non-migraine)\n             headache, defined as more than six headaches per month on average\n\n          -  Migraine attacks that were thought to be atypical and had consistently failed to\n             respond to medical therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "78 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1334", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978496", 
            "org_study_id": "A160-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Eletriptan 20 mg", 
                "description": "20mg oral", 
                "intervention_name": "Eletriptan 20 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Eletriptan 40 mg", 
                "description": "40mg oral", 
                "intervention_name": "Eletriptan 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Eletriptan 80 mg", 
                "description": "80mg oral", 
                "intervention_name": "Eletriptan 80 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Eletriptan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 11, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A160-102&StudyName=Efficacy%2C%20Safety%2C%20and%20Tolerability%20of%20Oral%20Eletriptan%20for%0ATreatment%20of%20Acute%20Migraine"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter Double-blind, Randomized Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects With Acute Migraine", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 1997", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A headache response was defined as a subject having improvement in headache severity from grade 2 or 3 at baseline to 0 or 1 at two hours post-dose.", 
            "measure": "Headache responder rate at two hours after the first dose for the first attack.", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978496"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pain free response was defined as improvement from grade 2 or 3 at baseline to grade 0 at two hours post-dose.", 
            "measure": "Pain free responder rate at two hours after the first dose for the first attack.", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 1996", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}